Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
Xenon XE 133 is an inhaled xenon gas radiopharmaceutical approved in 1976 for pulmonary imaging and ventilation assessment. It is used as a diagnostic agent to visualize lung function and detect abnormalities in breathing patterns. The product works as a radioactive tracer that distributes through inhalation to map ventilation in the lungs.
This aging diagnostic product faces moderate competitive pressure (30/100) with limited career expansion potential as revenue declines and the market consolidates around newer imaging modalities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Xenon XE 133 offers limited career growth opportunities as the product approaches loss of market relevance due to technology displacement and declining clinical adoption. Roles are primarily defensive—focused on maintaining existing revenue and managing stakeholder relationships in a shrinking nuclear medicine segment.
Worked on XENON XE 133 at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.